$XBI $123.60 +0.31%
Covid Updates
$MRNA +1.9% Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older. source
$AZN -1.1% AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US. source
Pipeline Updates
$ELDN -1.0% Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress. source
$CRSP +0.1% CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data. source
$ONCT +1.0% Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets. source
$VYNE -5.6% VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne. source
$TCRR +1.4% TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy. source
$ZYME -2.4% Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors. source
$OTLK +0.5% Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase. source
$IMAB +2.9% I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting. source
$CHRS +2.3% Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial. source
$URGN +1.1% The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC). source
$VTGN +3.0% VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain. source
$ADAP +0.2% Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings. source
$BHVN -0.2% Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment. source
$MRNS -2.8% Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event. source
$UBX -4.3% UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease. source
$KLDO -9.6% Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis. source
$ANVS -13.2% Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease. source
Financial & Business Updates
$SBBP +1.5% & $XERS -0.8% Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. source
$GMTX +0.3% Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy. source
Posted by FS
Comentários